The latest update is out from BiomX ( (PHGE) ).
On February 25, 2025, BiomX Inc. announced a securities purchase agreement involving a registered direct offering and concurrent private placement, expected to generate approximately $12 million in gross proceeds. The funds will support the Phase 2b clinical study of BX004, a phage cocktail for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, with results anticipated in Q1 2026. The offerings, led by Deerfield Management Company and the Cystic Fibrosis Foundation, are set to close around February 27, 2025, and include a reduction in exercise price for existing warrants. This strategic move aims to advance BiomX’s clinical programs and strengthen its position in the phage therapy market.
More about BiomX
BiomX is a clinical-stage company focusing on developing natural and engineered phage therapies aimed at targeting and eliminating harmful bacteria. Their primary market focus is on treating chronic diseases with significant unmet needs, such as cystic fibrosis and diabetic foot osteomyelitis.
YTD Price Performance: 2.56%
Average Trading Volume: 86,168
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $14.54M
For a thorough assessment of PHGE stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com